Posts Tagged: "Robert Bahr"

Join us for a free CLE webinar where we will discuss the processes and policies driving the USPTO. Topics during this casual conversation with the Commissioner and Deputy Commissioners for Patents will include hot issues affecting the Office, how they ensure quality, patent examination policy, how they are using AI, and much more. We have assembled a stellar panel of…

The memorandum points to Amgen for stating that the “newly characterized antigen” test could not stand because it contradicted the quid pro quo of the patent system whereby in order to obtain a patent one must describe an invention (the antibody, not the antigen recognized by the antibody). The memorandum states that in view of Amgen, “adequate written description of a newly characterized antigen alone should not be considered adequate written description of a claimed antibody to that newly characterized antigen, even when preparation of such an antibody is routine and conventional.”